- Home
- NTRA
NTRA
Natera Inc.
as 10-29-2025 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 24.9B | IPO Year: | 2015 |
| Target Price: | $196.24 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $119.29 - $198.99 | Next Earning Date: | 11-07-2025 |
| Revenue: | $1,964,250,000 | Revenue Growth: | 44.38% |
| Revenue Growth (this year): | 24.17% | Revenue Growth (next year): | 15.57% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 29 '25 | Sell | $190.35 | 1,867 | $355,924.59 | 64,626 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 28 '25 | Sell | $191.46 | 1,198 | $229,371.36 | 115,061 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Oct 28 '25 | Sell | $191.46 | 1,058 | $202,566.69 | 201,699 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Oct 28 '25 | Sell | $191.46 | 928 | $177,676.64 | 150,699 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 28 '25 | Sell | $191.27 | 2,415 | $461,648.12 | 64,626 | |
| Sheena Jonathan | NTRA | Director, Other | Oct 28 '25 | Sell | $191.46 | 191 | $36,569.22 | 235,730 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Oct 28 '25 | Sell | $191.46 | 3,680 | $704,579.79 | 149,840 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 27 '25 | Sell | $192.32 | 1,008 | $193,862.59 | 115,061 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Oct 27 '25 | Sell | $192.32 | 935 | $179,822.94 | 201,699 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Oct 27 '25 | Sell | $192.32 | 781 | $150,205.04 | 150,699 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
Simply Wall St.
2 days ago
Does Signatera’s Positive Phase 3 Data Shift the Long-Term Growth Story for Natera (NTRA)?
Simply Wall St.
2 days ago
How Recent Developments Are Reshaping the Natera Investment Story
Simply Wall St.
3 days ago
Natera (NTRA): Assessing Valuation After Pivotal Clinical Data Boosts FDA Prospects for Signatera
StockStory
9 days ago
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
StockStory
9 days ago
Why Are Natera (NTRA) Shares Soaring Today
Business Wire
10 days ago
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Simply Wall St.
17 days ago
The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.